高流量鼻導管氧氣治療全球市場：成長、趨勢、預測（2020年～2025年）

High-flow Nasal Cannula Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: 2022年01月17日 | 出版商:

Mordor Intelligence Pvt Ltd | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全貌
簡介
目錄

簡介

預估全球高流量鼻導管氧氣治療市場將在預測期間內以約12.4％的CAGR成長。市場成長主要可歸因於氣喘、COPD、慢性支氣管炎、肺氣腫等呼吸系統疾病的罹病率增加。根據世界衛生組織，約有2億3,500萬人患有氣喘。此外，超過80％的氣喘相關死亡發生在中低所得國家。

根據美國疾病管制與預防中心有1,600萬人受到COPD影響，隨著病患術增加也隨之推動市場成長。同時，高流量鼻導管治療系統的技術進步也促進市場發展。但由於其較一般的導管成本更高、且更為複雜，因而抑制了市場成長。

本報告研究全球高流量鼻導管治療市場，彙整市場機會及趨勢、成長及阻礙因素、按區分和區域的市場分析、競爭情勢、主要企業簡介等情報。

The High-flow Nasal Cannula market is projected to grow with a CAGR of nearly 12.4% over the forecast period. The major factor attributing to growth of the market is the increase in prevalence of respiratory diseases like asthma, COPD, Chronic Bronchitis, Emphysema etc. According to the World Health Organization, around 235 million people are living with asthma. Over 80% of asthma-related deaths occur in lower-middle income countries.

According to Centres for Disease Control and Prevention, 16 million people are affected by COPD. As the number of patients increase, the market growth also rises. Furthermore, technological advancements in the high flow nasal cannula systems is also boosting the market growth. However, the limitations to the high flow nasal cannula like higher cost than the normal cannula and increased complexity constraints the market growth.

Key Market Trends

Chronic Obstructive Pulmonary Disease Segment is Dominating the High-flow Nasal Cannula Market.

High flow nasal cannula therapy is effective in improving the oxygenation status in patients with Chronic Obstructive Pulmonary Disease accompanied by any disease. The dominant share of the segment is due to the increasing prevalence of the disease. According to Centers for Disease Control and Prevention, in the year more than 250 million people around the world had COPD for the year 2017, and it is predicted that the number will continue to rise in the forecast period. In patients with COPD, the application of HFNC postextubation significantly decreased the neuroventilatory drive and work of breathing compared with conventional oxygen therapy. HFNC, as compared with conventional Oxygen therapy, significantly decreases the neuroventilatory drive and the work of breathing in patients with COPD. As the prevalence of COPD increases and the product advancements boost the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of respiratory diseases in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to Centers for Disease Control and Prevention, about 9 million adults were diagnosed with chronic bronchitis, and about 3.5 million adults were diagnosed with emphysema in the year 2017 only in the United States. As per the statistics the the increasing patient pool and increasing disposable revenue in this country boosts the market growth of the region.

Competitive Landscape

The High-flow Nasal Cannula market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are ResMed, Fisher & Paykel Healthcare Limited, Devatec, Teleflex Incorporated, Smiths Medica, Vapotherm, Hamilton Medical, Flexicare Medical Limited, TNI medical AG, Great Group Medical Co., Ltd.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Rising Incidence of Respiratory Disorders
- 4.2.2 Technology Advances in the High-flow Nasal Cannula Systems
4.3 Market Restraints
- 4.3.1 Limitations of the High-flow Nasal Cannula Therapy
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Component
- 5.1.1 Air/Oxygen Blender
- 5.1.2 Active Humidifier
- 5.1.3 Single Heated Tube
- 5.1.4 Nasal Cannula
- 5.1.5 Other Consumables
5.2 By Application
- 5.2.1 Acute Respiratory Failure
- 5.2.2 Chronic Obstructive Pulmonary Disease
- 5.2.3 Acute Heart Failure
- 5.2.4 Others
5.3 Geography
- 5.3.1 North America
  - 5.3.1.1 United States
  - 5.3.1.2 Canada
  - 5.3.1.3 Mexico
- 5.3.2 Europe
  - 5.3.2.1 Germany
  - 5.3.2.2 United Kingdom
  - 5.3.2.3 France
  - 5.3.2.4 Italy
  - 5.3.2.5 Spain
  - 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
  - 5.3.3.1 China
  - 5.3.3.2 Japan
  - 5.3.3.3 India
  - 5.3.3.4 Australia
  - 5.3.3.5 South Korea
  - 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
  - 5.3.4.1 GCC
  - 5.3.4.2 South Africa
  - 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
  - 5.3.5.1 Brazil
  - 5.3.5.2 Argentina
  - 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
- 6.1.1 ResMed
- 6.1.2 Fisher & Paykel Healthcare Limited
- 6.1.3 Devatec
- 6.1.4 Teleflex Incorporated
- 6.1.5 Smiths Medical
- 6.1.6 Vapotherm
- 6.1.7 Hamilton Medical
- 6.1.8 Flexicare Medical Limited
- 6.1.9 TNI medical AG
- 6.1.10 Great Group Medical Co., Ltd